Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Number of participants who report cocaine use and have positive urine drug screens in the Chantix group versus the placebo group comparator [ Time Frame: Three times per week in weeks 2 through 13 ]
Number of subjects with cocaine abstinence as measured through three-times-weekly urine benzoylecgonine (BE) levels in urine drug screen (UDS) and self-reports of use from the Time Line Follow Back. UDS results and TLFB reports combined to yield daily use/no-use indicators for each study day of treatment.
Secondary Outcome Measures
Number of participants who are compliant with taking medications in the Chantix group versus the placebo group comparator [ Time Frame: Three times per week during weeks 2 through 13 ]
Measured through observed dosing at three-times-weekly clinic visits and weekly pill counts on the basis of self-reports and examination of blister packs.
Number of participants who report cocaine craving in the Chantix group versus the placebo group comparator [ Time Frame: Once per week in weeks 2 through 13 ]
As measured by weekly scores on the Cocaine Craving Questionnaire (CCQ) and the Minnesota Cocaine Craving Scale (MCC) during the medication treatment phase.
Number of participants who have smoked cigarettes, both in isolation and in relation to cocaine use in the Chantix group versus the placebo group comparator. [ Time Frame: Once per week in weeks 2 through 13 ]
Measured by carbon monoxide (CO) by CO monitor and cotinine levels using urinary cotinine dipstick testing at each clinic visit.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males and females, 18 to 65 years old.
Meets DSM-IV criteria for Cocaine Dependence, as determined by the Structured Clinical Interview for DSM-IV (SCID).
Live within a commutable distance of the Treatment Research Center (TRC) at the Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to be a distance within the service area of Septa, within an hour drive, or a distance that both the patient and Principal Investigator (PI) find acceptable.
Understands and signs the informed consent.
Current DSM-IV diagnosis of any psychoactive substance dependence other than cocaine, alcohol, or nicotine dependence, as determined by the SCID.
Subject is, in the investigator's opinion, at risk of requiring medical detoxification for alcohol dependence during the study.
Concomitant treatment with psychotropic medications.
Current gambling problems. This will be assessed by the patient's self-report.
Patients mandated to treatment based upon a legal decision or as a condition of employment who will use participation in this study to fulfill to their court mandated treatment requirement.This will be assessed by the patient's self-report.
Current severe psychiatric symptoms, e.g., psychosis, dementia, suicidal or homicidal ideation, mania or depression requiring antidepressant therapy in the opinion of the Principal Investigator (PI).
Use of any investigational medication within the past 30 days.
Subject has serious heart, lung, kidney, immune system, GI tract (ulcerative colitis, regional enteritis, or gastrointestinal bleeding) disease.
Current use of naltrexone, disulfiram, modafinil, stimulants, haloperidol, benzodiazepines or anticonvulsants.
Known hypersensitivity to varenicline.
Patients with known AIDS or other serious illnesses that may require hospitalization during the study.
Female subjects who are pregnant or lactating, or female subjects of child-bearing potential who are not using acceptable methods of birth control. Acceptable methods of birth control include:
Patients with impaired renal function as indicated by corrected creatinine clearance below 60 ml/min as determined by the modified Cockcroft equation (CDC, 1986).
Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits that are clinically unacceptable to the Medical Director. EKG 1st degree heart block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are allowed; liver function tests [LFTs] <5 x ULN are acceptable).
Physiological Effects of Drugs
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators